Epitracker aims to help people live longer and healthier. Our longevity program has resulted in discovery of approximately one hundred promising molecules, including our lead micronutrient, ETI-101, to protect cells against the aging process. ETI-101 is being advanced to market through an Epitracker spinout, Seraphina Therapeutics, Inc. Additional compounds, including ETI-1029 and ETI-1080, are being advanced to support healthy aging,
Promising molecules to expand longevity
|
Our longevity compound library includes molecules that may help to detect, prevent, and treat key conditions that impair our longevity and quality of life, including:
|
ETI-101 for anemia of inflammation
ETI-101 is a small molecule targeting both clinical diseases and anti-aging mechanisms.
Anemia of Inflammation
|
As we age, we are more likely to develop chronic, low-lying systemic inflammation and fragile red blood cells, which results in anemia of inflammation. Anemia of inflammation is the most common type of anemia in the elderly. An estimated 77% of people older than 85 years old have anemia of inflammation, which increases the risks of:
|
|
ETI-101 Efficacy
ETI-101 has demonstrated repeatable efficacy across multiple mammalian models. ETI-101 attenuated the following indices in models with disease:
- Alleviated anemia (raised hemoglobin, hematocrit, and RBCs)
- Lowered inflammation (lowered globulins, MCP-1, IL-6)
- Lowered liver iron deposition in animal model for NASH
- Reduced liver fibrosis severity in animal model for NASH
- Lowered cholesterol, triglycerides, glucose and insulin
ETI-101 Healthy Aging Mechanisms
Our studies to date support ETI-101's anti-aging mechanisms, including:
- Improved cell membrane integrity/resilience
- Improved mitochondrial function
- Upregulation of the AMP-activated protein kinase (AMPK) signaling pathway
- AMPK activation (phosphorylation)
- Predicted raised levels of geroprotective miRNA
ETI-101 Cell-Based Activity
In human cell-based systems mimicking a variety of disease states, ETI-101 has demonstrated significant dose-response anti-inflammatory and antifibrotic activity, including:
- Lowered MCP-1 (a pro-inflammatory chemokine)
- Lowered secreted immunoglobulin G
- Lowered Collagen I
- Lowered fibroblast proliferation
ETI-101 Safety
ETI-101 has a strong safety profile. To date, ETI-101 has demonstrated no cytotoxicity (using 12 human cell systems at four concentrations) and no off-target effects (using 78 functional assays at 10 concentrations).
ETI-035 and ETI-059 for cachexia
ETI-035 and ETI-059 are being developed to treat aging-associated weakness and wasting of the body (cachexia) due to severe illness, poor appetite and cognitive impairment. ETI-035 and ETI-059 are partial cannabanoid 1 receptor (CNR1) agonists that may help increase appetite and cognitive function in the elderly.
ETI-1029 and ETI-1080 for inflammaging
|
ETI-1029 is an amino acid that hat decreases with age in long-lived mammals. ETI-1029 is demonstrating mitochondrial protective and anti-inflammatory activities in human cell systems mimicking lipid peroxidation and inflammation. ETI-1029 significantly reduced macrophages, inflammatory cells that increase with age and have been proposed as a key players in inflammaging.
ETI-1080 is a xenobiotic that decreases with age in long-lived mammals. Higher blood levels of ETI-1080 are associated with lower glucose, cholesterol, triglycerides, insulin and liver enzymes; and higher red blood cells and hemoglobin. As part of a Phase II Small Business Innovation Research (SBIR) project set to be funded by the Office of Naval Research, Epitracker will be investigating the pharmacokinetics, activities and efficacies of ETI-1029 and ETI-1080 to better understand their potential as a means to prevent or treat inflammaging and other comorbidities of aging. |
|
